EMA Withdrawn: Hexavac (purified diphtheria toxoid;purified tetanus toxoid;purified pertussis toxoid;purified pertussis filamentous haemagglutinin;hepatitis B surface antigen;Inactivated Type 1 Poliovirus (Mahoney);Inactivated Type 3 Poliovirus (Saukett);Haemophilus influenzae type b polysaccharide) — Sanofi Pasteur MSD, SNC

View source ↗

Summary

The EMA has withdrawn Hexavac, a hexavalent combination vaccine, from the market. The decision was taken in 2012 and concerns multiple indications including Hep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Hepatitis B
• Meningitis Haemophilus Influenzae Type
• Poliomyelitis
• Tetanus
• Whooping Cough

Drugs mentioned

• Hexavac (DTPa-HBV-IPV-Hib hexavalent vaccine)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis B;Tetanus;Immunization;Meningitis, Haemophilus;Whooping Cough;Poliomyelitis;Diphtheria. MAH: Sanofi Pasteur MSD, SNC. Decision date: 28/06/2012